Silo Pharma, Inc. - Common Stock (NQ:SILO)

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study

January 24, 2024

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗

January 12, 2024

Via Benzinga

Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗

January 07, 2024

Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury

Via Benzinga

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Successfully Completes First Phase of Dose-Ranging SPC-15 Study

January 04, 2024

Silo Pharma Concludes First Phase of Dose-Ranging Study Of Intranasal Treatment For Post Traumatic Stress Disorder ↗

January 04, 2024

Thursday, Silo Pharma Inc (NASDAQ: SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD).

Via Benzinga

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

January 04, 2024

Fibromyalgia Care Breakthrough: DEA Green Lights Biotech Partnership Exploring Ketamine Implant Therapy ↗

December 28, 2023

Silo Pharma’s (NASDAQ: SILO) novel ketamine-loaded implant targeting fibromyalgia and chronic pain conditions, SP-26, is reportedly ad

Via Benzinga

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Regulatory Approval for Ketamine Implant, Moves Forward with Partner to Next Stage of Development

December 28, 2023

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

December 28, 2023

Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗

December 27, 2023

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...

Via Benzinga

Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More ↗

December 18, 2023

Biden To Decide On Psychedelic Therapy Bill

Via Benzinga

Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More ↗

December 11, 2023

John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy

Via Benzinga

SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying ↗

December 08, 2023

The Dow Jones closed higher by over 60 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More ↗

December 05, 2023

Defense Dept. Funds Ketamine Study For PTSD Treatment

Via Benzinga

Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More ↗

November 24, 2023

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan

Via Benzinga

Topics Cannabis

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 23, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 22, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 21, 2023

Via Benzinga

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Inks Exclusive License Agreement with Medspray Pharma BV

November 21, 2023

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 21, 2023

Via Benzinga

November 21, 2023

Silo Pharma Collaborates With Medspray Pharma For Intranasal Technology For Stress Disorder Candidate ↗

November 21, 2023

Silo Pharma Inc (NASDAQ: SILO) announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 17, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

November 17, 2023

It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 15, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 15, 2023

It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday!

Via InvestorPlace

Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More ↗

November 12, 2023

Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?

Via Benzinga

Topics Initial Public Offering

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Initiate Dose-Ranging Study, Positioning for Early Start of Phase 1 Clinical Trial of SPC-15

November 08, 2023

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

November 08, 2023

Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trial